Charles O. (Chip) Rutledge
Ph.D. in Pharmacology - 1966 Harvard
NATO Postdoctoral Fellow in Pharmacology - 1966-67 Gothenburg, Sweden
University of Colorado School of Medicine - 1967-75
Chairman of the Department of Pharmacology and Toxicology, University of Kansas School of Pharmacy - 1975-87
Dean of the Schools of Pharmacy, Nursing, and Health Sciences, Purdue University - 1987-2002
Dr. Rutledge has been very active in the American Association of Colleges of Pharmacy, serving as Chair of the Council of Faculties, Chair of the Council of Deans, and Association President in 1996-97. He has also served on the Volwiler Award Committee, the Research and Graduate Affairs Committee, the Committee on the Present and Future Needs of the Council of Faculties, the Academic Management System Organizing Committee, and was a member of the Commission on Implementing Change in Pharmacy Education. Dr. Rutledge is a registered pharmacist in Kansas and Indiana. He served as the first Chair of the Indiana Drug Utilization Review Board.
Dr. Rutledge served as President of the American Society for Pharmacology and Experimental Therapeutics from 1996-97. He has served as Councilor and Treasurer of this organization. He currently is the Chairman of the Investment Subcommittee of the Finance Committee. His interest in financial affairs was also demonstrated when he served as Treasurer of the Federation of American Societies for Experimental Biology from 1994-96. He was Field Editor for the Journal of Pharmacology and Experimental Therapeutics and Editor of Biogenic Amines. Dr. Rutledge has been a member of two NIMH Review Committees and the NIGMS Pharmacological Sciences Review Committee, which reviews training grants in the pharmacological sciences.
Dr. Rutledge has published over 150 papers and abstracts in the field of neuropharmacology. His research includes establishment of a model for studying the mechanism by which amphetamine releases biogenic amine neurotransmitters from nerve endings. He has also conducted studies on the biochemical-behavioral correlates in the use of levodopa for the treatment of Parkinsonism. Other studies have involved an examination of the lipid micro-environment of nerve endings as a determinant of the activity of proteins involved in neurotransmission.
Rutledge, C.O.: Stories from a Life of Learning. Am. J. Pharm. Ed. 66, 329-332, 2002.
Cohen, J.L., Kabat, H.F., Koda-Kimble, M.A. and Rutledge, C.O.: Are we delivering on our promise to society to assure the safe use of medications? Report of the AACP Argus Commission 2000-2001. Am. J. Pharm. Ed. 65, 6S-8S, Winter Supplement 2001.
Rutledge, C.O.: Accountability for misconduct in science. Am. J. Pharm. Ed. 60, 425-426, 1996.
Rutledge, C.O.: Paying attention to the wonder and skepticism of science. Am. J. Pharm. Ed. 60, 395-398, 1996.